Malaria Drug Development and Resistance Control
Thursday, 03 July 2014 09:00 - 17:00
Cineworld: The O2, London, SE10 0DX, UK
The prevention of anti-malarial drug resistance is of enormous public health importance. It can be assumed that no therapy currently under development or to be developed in the foreseeable future will be totally protective against malaria. This event will discuss the development of new treatments for malaria together with the use of current drugs to limit, insofar as it is possible, any further development of resistance. There will be plenty of opportunity for delegates to present their work and network in an informal atmosphere, with a lot of time given for discussion and debate.
This event has CPD accreditation and is part of The Beating Malaria Summit London 2014 BeatingMalariaLondon2014.com
The deadline for abstract submissions for oral presentation is April 10th 2014.
Abstracts for poster presentation only can be submitted up to two weeks before the event.
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Talk times include 5 – 10 minutes for questions
9:00 – 9:30 Registration
9:30 – 9:50 Development of enantiomerically pure aminoalcohol quinoline derivatives to improve their antimalarial efficiency and assessment of their activity against Plasmodium falciparum in combination with dihydroartemisinin
Dr Catherine Mullié, Assistant Professor , Faculté de Pharmacie, Université de Picardie Jules Verne, France
In an attempt to reduce side-effects induced by mefloquine and try to avoid resistance, a series of enantiomerically pure amino alcohol quinoline derivatives structurally close to mefloquine but with a single asymmetric carbon has been synthesized. The activity of (S)-derivatives was compared to that of their (R)-counterparts on mefloquine-sensitive and –resistant strains of Plasmodium falciparum. The (S)-derivatives were found to be 2 to 10 times more active and retained their activity on a strain with a reduced sensitivity to mefloquine. As the current policy to avoid the increase in P.falciparum resistant strains is to combine drugs, the in vitro activity of the more promising compounds of this series in combination with dihydroartemisinin will also be discussed.
9:50 – 10:10 Natural products as a source of new drugs and/or herbal treatments for malaria
Dr Colin Wright, Reader in Pharmacognosy, Bradford School of Pharmacy, University of Bradford, UK
Many plant species are used traditionally for the treatment of malaria. Since the important antimalarials, quinine and artemisinin are obtained from Cinchona species and Artemisia annua respectively, it is not unreasonable to expect that plant species may yield further potent antimalarials. Using the West African species Cryptolepis sanguinolenta as an example, the potential of natural sources to yield new antimalarials will be explored. A limitation of antimalarials such as artemisinin is that they are often not available and/or affordable to many of those who need them, especially in Africa and this has led to the promotion of herbal treatments for malaria. In this presentation the effectiveness of A. annua has a herbal treatment for malaria will also be discussed.
10:10 – 10:30 Talk title to be confirmed
Professor Maria Victoria Valero-Bernal, Universidad Nacional de Colombia, Colombia
10:30 – 11:00 Speakers’ photo then mid-morning break and poster exhibition and trade show
11:00 – 11:20 Talk title to be confirmed
Dr Glenn McConkey, Senior Lecturer, School of Biology, University of Leeds, UK
11:20 – 11:40 Talk title to be confirmed
Dr Kathy Andrews, Associate Professor, Tropical Parasitology Lab, Griffith University, Australia
11:40 – 12:30 Oral Presentations
12:30 – 13:30 Lunch, poster exhibition and trade show
13:30 – 14:15 Question and Answer Session
14:15 – 14:35 Talk title to be confirmed
Dr Mohga Kamal-Yanni, Senior health & HIV policy advisor, Oxfam GB
14: 35 – 14:55 Talk title to be confirmed
Dr Ian Hastings, London School of Tropical Medicine, UK
14:55 – 15:30 Afternoon Tea, last poster session and trade show
15:30 – 15:50 Malaria control: the nutraceutical potential of natural cocoa powder
Professor Frederick Addai, Academic Researcher, University of Ghana Medical School
Historical and extant anecdotal evidence and limited empirical validation evince antimalarial activity of natural cocoa powder. Persuasive literature abound on how dietary nutrients in cocoa powder may act individually and synergistically to afford protection from clinical malaria. The tropical regions that produce cocoa roughly overlap those that are malaria endemic. Echoing the reasoning that effective malaria control strategies should combine interventions adapted to local needs based on specific ecological, epidemiological, economic and social conditions, this talk advocates natural cocoa as diet-mediated antimalarial prophylaxis. Multi-nutrient and multiple mechanistc potential makes parasite resistance to natural cocoa very unlikely.
15:50 – 16:10 Antimalarials that improve immune response
Professor José M. Bautista, Complutense University of Madrid, Madrid, Spain
Blood-stage Plasmodium parasites are the main cause of disease and death during malaria infection, and important inducers of naturally acquired immunity. However, these asexual stages do not seem to elicit efficient long-term immune responses. In our lab we have observed that anti-malarial compounds with a “delayed-death” effect promote effective immune responses in preclinical studies. Whereas no vaccine for this disease has yet been licensed, combined therapy including a parasitostatic agent to promote long-term immune protection in infected patients could be a candidate strategy to control malaria.
16:10 - 16:30 Talk title to be confirmed
Mr Aditya Jha, Centre for Cellular and Molecular Biology, India
16:30 - 17:00 Chairman’s Summing Up
Registration Website: http://www.regonline.co.uk/malariadrug2014
About the Speakers
Catherine Mullié obtained a PhD in Microbiology and a PharmD at the University of Lille, France, in 1999. After a post-doc year at the Faculté de Medicine in Amiens (Laboratoire d’Immunologie, INSERM-EMI 0351), she became assistant professor at the Faculté de Pharmacie in Amiens in 2000 and joined the LG-2A (Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, FRE-CNRS 3517) in 2008, in the team headed by Pr. Sonnet. The team current research is focused on the development of new antimicrobial and antimalarial drugs, with a special interest in the synthesis and biological evaluation of molecules bearing asymmetric carbons.
Colin Wright studied pharmacy at the School of Pharmacy, University of London, and worked in hospital and community pharmacy before returning to carry out research on antimalarial and antiamoebic natural products, obtaining his Ph.D in 1989. He has continued his research at Bradford School of Pharmacy since 1994 particulary on the theme of antimalarial drug development from natural products.
Frederick Addai is an Associate Professor, whose 10-year research in 2004 affirmed healthful gains of consuming good cocoa products. He has supervised ten graduate studies on health benefits of cocoa, and spawned many more independent studies. Personal, and community anedcotal experiences with daily consumtpion of cocoa as unsweetned beverage, provoked research that confirms antimalarial activity of natural cocoa. He has given numerous print and electronic media presentations locally and internationally; including invited talks at the 15th International Cocoa Research Conference (ICRC) in Costa Rica, and 69th General Assembly and Council of Ministers Meeting of the Cocoa Producers’ Alliance (COPAL), Abidjan, La Cote d’Ivoire.
José M. Bautista obtained his Ph.D. in 1987, completed postdoctoral training at the University of London-Royal Postgraduate Medical School, and joined the faculty of Complutense University of Madrid as an Assistant Professor in 1991. He has been visiting scientist at Imperial College of Medicine –Hammersmith Hospital (London), Institute of Genetics and Biophysics (Naples), University for Developmental Studies (Tamale-Ghana) and Cheikh Anta Diop University (Dakar-Senegal). Full Professor since 2007 at present direct the Department of Biochemistry and Molecular Biology IV at Complutense University of Madrid and the research group Translational Haematology II at the Research Institute Hospital 12 de Octubre in Madrid. Dr. Bautista’s research is on improving preclinical models of malaria and highthoughput proteomic methods to determine long term effect of antimalarials including immune response.
Post expires at 10:38am on Thursday July 3rd, 2014
Tags: 4-aminoquinolone, Amodiaquine, Antimalarial, antimalarial efficacy, Artemisinin, Atovaquone, Chloroquine, Clindamycin, combination, combination therapies, cryptolepine, dihydroartemisinin, Doxycycline, Halofantrine, Immune response, malaria, Mefloquine, Mefloquine derivatives, Parasitostatic, Plasmodial control, Polyphenols, Primaquine, Proguanil, prophylaxis, Pyrimethamine, Quinine, Resistance, stereochemistry, therapy, traditional antimalarial plants
